Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2020-03-09
Target enrollment:
Participant gender:
Summary
This study is a Multicentre, Open-label, Phase II study of Daratumumab and Dexamethasone in
MM patients. Eligible patients must have a symptomatic RRMM with a measurable disease,
resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide.
There is no dose escalation phase, as the MAxiamal Tolerated Dose (MTD) and drug scheduling
have already been determined in previous phase 1-2 dose escalation studies. There is no
randomization.